Last updated: September 8, 2026
Activase, Genentech’s recombinant alteplase, remains an important hospital thrombolytic for acute ischemic stroke, acute myocardial infarction, and pulmonary embolism. Its core patent protection has expired, and no current Orange Book exclusivity protects the product. Commercial durability depends on clinical protocols, emergency-department access, hospital supply reliability, and competition from tenecteplase rather than on patent exclusivity. Roche does not separately disclose Activase revenue, so its financial trajectory must be assessed through product demand, competitive substitution, and portfolio reporting.
What is Activase and how is it used?
Activase is the brand name for alteplase, a recombinant form of human tissue plasminogen activator. It converts plasminogen to plasmin and promotes fibrinolysis.
The FDA-approved product is supplied as a sterile lyophilized powder for intravenous administration in 50-mg and 100-mg single-dose vials. Its labeled uses include:
| Indication |
Commercial relevance |
| Acute ischemic stroke |
Largest strategic market and the primary area exposed to tenecteplase substitution |
| Acute myocardial infarction |
Long-established use, but declining relative importance as interventional cardiology expanded |
| Pulmonary embolism |
Hospital and emergency-care use, including selected high-risk cases |
The FDA originally approved Activase in 1987. The current label includes weight-based and indication-specific dosing regimens, with administration controlled by hospital protocols and emergency physicians, neurologists, cardiologists, and critical-care specialists (U.S. Food and Drug Administration [FDA], 2022).
What is the financial trajectory of Activase?
Activase revenue is no longer separately reported by Roche or Genentech in the companies’ principal public financial disclosures. Roche reports consolidated pharmaceutical revenue and highlights major growth products, but Activase is not generally presented as a standalone revenue line in recent annual reports (Roche, 2024).
This prevents a reliable current product-level revenue estimate from public filings. The commercial trajectory can nevertheless be characterized as mature and structurally pressured.
| Financial driver |
Effect on Activase |
| Patent expiry |
Removes premium protection and lowers barriers to competing alteplase products |
| Stroke treatment volume |
Supports demand, particularly in comprehensive stroke centers |
| Tenecteplase adoption |
Creates direct substitution risk in acute ischemic stroke |
| Myocardial infarction practice |
Limits growth because mechanical reperfusion has reduced fibrinolytic use in many settings |
| Hospital purchasing |
Increases price sensitivity and favors reliable supply |
| Roche portfolio strategy |
Makes Activase a mature-product contributor rather than a disclosed growth driver |
Activase can retain meaningful cash generation even without patent exclusivity because thrombolytics are administered in time-critical settings. Hospitals must maintain inventory, and treatment decisions often prioritize protocol familiarity and supply availability. Revenue growth, however, is more likely to come from price, utilization recovery, or share retention than from new indications.
How does tenecteplase compare with Activase?
Tenecteplase is the principal competitive threat to Activase in stroke. Tenecteplase is a genetically modified form of tissue plasminogen activator with greater fibrin specificity and a longer half-life. Its pharmacologic profile permits single-bolus administration, whereas alteplase generally requires an initial bolus followed by an infusion.
The FDA approved TNKase, tenecteplase, for acute ischemic stroke in March 2024. Tenecteplase had already been approved for acute myocardial infarction, giving its manufacturer a broader thrombolytic commercial platform (FDA, 2024a).
| Factor |
Activase |
TNKase |
| Active ingredient |
Alteplase |
Tenecteplase |
| Administration |
Bolus plus infusion |
Single intravenous bolus |
| Stroke approval |
Established |
Approved in 2024 |
| Hospital workflow |
More complex |
Operationally simpler |
| Patent position |
Core protection expired |
More recent product and formulation protection |
| Main commercial risk |
Substitution by tenecteplase |
Formulary and guideline adoption |
| Manufacturer |
Genentech/Roche |
Genentech/Roche |
The competition is unusual because both products are marketed by Roche-affiliated organizations. Roche therefore has an incentive to manage internal substitution rather than defend Activase against an unrelated branded competitor. The likely portfolio outcome is a gradual migration of selected stroke use from Activase to TNKase, while Activase remains relevant where protocols, dosing preferences, procurement contracts, or clinical evidence favor alteplase.
When does Activase lose exclusivity?
Activase has already lost the exclusivity associated with its original approval and core composition-of-matter protection. The product was approved in 1987, and the principal patent estate for recombinant tissue plasminogen activator is no longer a meaningful barrier to competition.
Activase is a biologic approved under a biologics license application, not a conventional small-molecule drug approved under a new drug application. As a result, the key regulatory framework is the FDA’s Purple Book and the biosimilar pathway under section 351(k) of the Public Health Service Act, rather than the standard Orange Book patent-certification process used for small-molecule generics (FDA, 2024b).
Is Activase listed in the Orange Book?
Activase is not protected through a conventional Orange Book listing because it is regulated as a biologic. The relevant reference-product and biosimilar framework is the Purple Book.
No FDA-approved interchangeable or biosimilar alteplase product had been identified in the principal FDA biologics databases through 2024. The absence of an approved biosimilar does not restore patent exclusivity. It indicates that regulatory, manufacturing, clinical, and commercial barriers remain more important than surviving core patents.
What patents protect Activase?
The original Activase patent estate covered recombinant tissue plasminogen activator, production methods, protein variants, and pharmaceutical formulations. Those core rights have expired or reached the end of their effective commercial life.
| Protection category |
Current commercial position |
| Recombinant tPA composition |
Expired or commercially ineffective as a barrier |
| Manufacturing methods |
Historical importance; potential process know-how may remain confidential |
| Protein variants |
Relevant to later thrombolytic products, including tenecteplase, rather than durable Activase exclusivity |
| Lyophilized formulation |
No known current formulation barrier that prevents competition |
| Method-of-use patents |
Historical stroke, myocardial infarction, and pulmonary embolism claims do not provide current broad exclusivity |
| Regulatory exclusivity |
Original biologic exclusivity has long expired |
The remaining defensibility of Activase is therefore low from a patent perspective. Its practical protection comes from manufacturing experience, validated quality systems, hospital protocols, clinical familiarity, inventory relationships, and the difficulty of producing a highly purified recombinant protein at commercial scale.
What formulations are protected by Activase patents?
Activase is sold as a lyophilized injectable powder requiring reconstitution before administration. The product’s commercial formulation and vial presentation are established and familiar to hospitals.
Formulation protection is not currently the principal source of market power. A competing alteplase product would need to demonstrate comparable identity, purity, potency, stability, sterility, and immunogenicity. Those requirements create development and manufacturing hurdles, but they do not function like an unexpired composition patent.
The most relevant technical barriers include:
- Recombinant protein expression and recovery
- Control of proteolytic degradation
- Consistent fibrinolytic potency
- Viral safety and aseptic manufacturing
- Stability during storage and reconstitution
- Lot-to-lot comparability
- Clinical bridging or confirmatory evidence for a biosimilar applicant
What is the FDA regulatory status of Activase?
Activase remains FDA-approved for its labeled indications. The FDA-approved product is supplied by Genentech, a Roche company, and is distributed through hospital and specialty pharmaceutical channels.
The regulatory profile is mature:
| FDA milestone |
Status |
| Original approval |
1987 |
| Acute myocardial infarction |
Approved indication |
| Acute ischemic stroke |
Approved indication |
| Pulmonary embolism |
Approved indication |
| Biologic classification |
BLA-regulated product |
| Current exclusivity |
Expired |
| Biosimilar competition |
No approved biosimilar identified through 2024 |
| Orange Book patent status |
Not the primary regulatory listing framework |
The key regulatory development is the approval of tenecteplase for acute ischemic stroke. That decision gives hospitals an FDA-labeled alternative to alteplase and reduces Activase’s regulatory differentiation in its most strategically important indication (FDA, 2024a).
Which companies are challenging Activase?
The direct competitive field is limited.
Genentech and Roche
Genentech markets Activase and TNKase within the Roche group. Internal portfolio competition is likely to be more important than external branded competition. Roche can retain thrombolytic revenue while shifting use toward the newer product.
Biosimilar developers
Alteplase is theoretically eligible for biosimilar development under the 351(k) pathway. A developer would face a technically demanding recombinant-protein program and a market in which the incumbent product is mature and a newer branded alternative is gaining attention.
No major approved alteplase biosimilar competitor had entered the U.S. market through 2024. That limits immediate erosion from biosimilar substitution but does not eliminate future entry risk.
Tenecteplase manufacturers
Tenecteplase is the most credible commercial challenger because it offers simpler administration and has a newer patent and regulatory position. Its adoption depends on clinical guidelines, hospital protocols, payer economics, and comparative outcomes data.
What is the patent litigation and settlement status for Activase?
Public company filings and FDA-facing product information do not identify a current major patent litigation campaign involving Activase through 2024. There is no prominent current Paragraph IV litigation pathway comparable to litigation surrounding small-molecule drugs listed in the Orange Book.
Paragraph IV challenges are not the central mechanism for Activase because Activase is a biologic. A future competitor would more likely pursue a biosimilar application, a standalone biologics license application, or a competing thrombolytic product rather than file a conventional ANDA Paragraph IV challenge.
No material current settlement agreement between Genentech and an alteplase biosimilar developer has been publicly disclosed in the cited Roche and FDA materials.
What generic entry risks exist for Activase?
The near-term risk of conventional generic entry is low because Activase is a biologic. The medium-term risk from biosimilar or competing biologic entry is higher but remains constrained by manufacturing complexity and limited market growth.
The most important erosion scenarios are:
- Tenecteplase becomes the preferred thrombolytic for acute ischemic stroke.
- Hospitals use competitive bidding to reduce alteplase pricing.
- A biosimilar alteplase gains FDA approval and secures formulary access.
- Stroke networks standardize single-bolus tenecteplase protocols.
- Roche shifts promotional and supply resources toward TNKase.
Activase’s strongest defense is operational. Emergency departments have established alteplase workflows, dosing calculators, order sets, pharmacy procedures, and clinician familiarity. Those factors can delay switching even after a competing product becomes available.
How strong is the Activase patent estate?
The Activase patent estate is weak as a current exclusionary asset and moderate as a commercial franchise.
| Dimension |
Assessment |
| Core patent strength |
Low; original protection has expired |
| Regulatory exclusivity |
None of practical significance |
| Formulation protection |
Limited current value |
| Manufacturing barrier |
Moderate to high |
| Clinical familiarity |
High |
| Hospital switching costs |
Moderate |
| Competitive durability |
Dependent on protocols and supply |
| Revenue visibility |
Low because Roche does not separately report sales |
Activase is better viewed as a mature biologic franchise than as a patent-protected growth asset. Its value is tied to recurring hospital demand and Roche’s ability to manage the transition to tenecteplase.
What is the geographic coverage and international outlook?
Activase has been commercialized internationally under the Activase and Actilyse names. Market access, thrombolytic guidelines, reimbursement, and hospital infrastructure vary by country.
In markets with strong stroke-center networks and established alteplase protocols, Activase can retain substantial use. In markets where hospitals prioritize lower administration complexity or where tenecteplase receives favorable reimbursement, substitution risk is greater.
International pricing is also exposed to tender systems and government procurement. The absence of current patent protection increases the importance of supply contracts, regulatory registrations, and local manufacturing or distribution capability.
What are the key market dynamics through 2028?
The market outlook is mature rather than expansionary.
Base case
Activase remains a meaningful hospital thrombolytic, with stable or gradually declining volume. Stroke use partially shifts to TNKase, while Activase retains demand in hospitals with established protocols and in indications where alteplase remains preferred.
Downside case
Tenecteplase captures a large share of stroke treatment, and hospital tenders pressure Activase pricing. A biosimilar entrant would accelerate erosion if it secured broad formulary adoption.
Upside case
Growth in stroke diagnosis, faster treatment rates, expanded comprehensive stroke networks, or supply constraints affecting competitors could stabilize Activase demand. The upside is limited because the product is mature and lacks meaningful patent protection.
Key Takeaways
- Activase is recombinant alteplase marketed by Genentech and Roche.
- Its original patent and regulatory exclusivity have expired.
- Activase is regulated as a biologic and is not primarily protected through Orange Book listings.
- Roche does not separately disclose current Activase revenue.
- The main commercial threat is TNKase, Roche’s tenecteplase product, especially after FDA approval for acute ischemic stroke in 2024.
- No approved U.S. alteplase biosimilar had been identified through 2024.
- Activase’s remaining commercial strength comes from clinical familiarity, hospital protocols, supply infrastructure, and manufacturing complexity.
- Revenue is likely mature to declining, with the main risk being internal substitution by tenecteplase rather than conventional generic entry.
FAQs About Activase Market and Patent Risk
Does Activase still have patent protection?
Activase no longer has meaningful core patent protection. Its original recombinant tPA and formulation rights have reached the end of their commercial life.
Is Activase a biologic or a generic drug?
Activase is a biologic approved under a biologics license application. A competing product would generally pursue a biosimilar or standalone biologic pathway rather than a conventional ANDA generic pathway.
Can hospitals substitute TNKase for Activase?
Yes, where FDA labeling, hospital protocols, clinical guidelines, and formulary decisions support substitution. TNKase’s single-bolus administration is its main operational advantage.
Does Activase have biosimilar competition?
No FDA-approved alteplase biosimilar had been identified in the U.S. through 2024. Future competition remains possible under the biosimilar pathway.
Is Activase still commercially important to Roche?
Activase remains an established hospital product, but Roche does not separately report its revenue as a major disclosed growth product. Its strategic relevance is increasingly linked to Roche’s broader thrombolytic portfolio, including TNKase.
References
-
Roche Holding AG. (2024). Annual report 2023. Roche.
-
U.S. Food and Drug Administration. (2022). Activase (alteplase) prescribing information. Genentech, Inc.
-
U.S. Food and Drug Administration. (2024a). TNKase (tenecteplase) prescribing information. Genentech, Inc.
-
U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., Jauch, E. C., Kidwell, C. S., Leslie-Mazwi, T. M., Ovbiagele, B., Scott, P. A., Sheth, K. N., Soule, L., Summers, D. V., & Tirschwell, D. L. (2019). Guidelines for the early management of patients with acute ischemic stroke. Stroke, 50(12), e344-e418.
